Fluorinated Cyclic Dinucleotides as Oral Vaccine Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines have limited ability to elicit protective mucosal immunity, particularly for gastrointestinal infections, due to poor immunogenicity of subunit antigens and adverse effects of existing mucosal adjuvants, and there is a need for safe and effective adjuvants that can enhance immune responses at mucosal surfaces.
Innovation Solution
The use of fluorinated cyclic dinucleotides, such as 2′-F-c-di-GMP, as adjuvants in oral vaccines to enhance antigen-specific immune responses, including mucosal and humoral immunity, by providing stability and resistance to acid degradation in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholera toxin (CT) or heat labile toxin (LT) are used as mucosal adjuvants, then mucosal adjuvanticity is improved, but toxicity increases
Solution Approach 1:
The invention extracts and applies only the beneficial adjuvantic property of bacterial nucleotides (c-di-GMP, c-di-AMP) while eliminating the toxic effects associated with whole toxin molecules. By using purified nucleotide components rather than complete toxin structures, the patent separates the desirable immune-stimulating function from the harmful toxic effects.
Solution Approach 2:
The patent employs small, simple nucleotide molecules (c-di-GMP, c-di-AMP) that can be synthesized and administered without the complex structure and persistent toxicity of protein toxins. These nucleotide adjuvants provide effective immune stimulation with reduced adverse effects compared to traditional toxin-based adjuvants.
2Object-affected harmful factors
If detoxified derivatives of CT or LT are used, then toxicity is reduced, but adjuvanticity is lost or reduced
Solution Approach 1:
The invention introduces bacterial nucleotides (c-di-GMP, c-di-AMP) as intermediary molecules that mediate immune stimulation without requiring the complex toxin structures. These nucleotides act as safe intermediaries that trigger mucosal immune responses through pattern recognition receptors, bypassing the need for toxin-based mechanisms while maintaining adjuvanticity.
Solution Approach 2:
The patent changes the chemical parameters from complex protein toxin structures to simple nucleotide structures. This parameter change maintains the essential adjuvantic function (immune stimulation) while fundamentally altering the molecular properties to reduce toxicity and improve safety profile.
3Object-affected harmful factors
If subunit antigens are used, then safety is improved, but immunogenicity deteriorates
Solution Approach 1:
The patent uses simple, well-defined nucleotide adjuvants (c-di-GMP, c-di-AMP) that can be easily synthesized and administered. These small nucleotide molecules provide potent immune stimulation when combined with subunit antigens, overcoming the poor immunogenicity of subunit vaccines while maintaining the safety advantages of non-replicating, defined components.
Data Source
AI summary
Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.